Enhanced Anandamide Plasma Levels in Patients with Complex Regional Pain Syndrome following Traumatic Injury: A Preliminary Report

I. Kaufmann a D. Hauer a V. Huge a M. Vogeser b P. Campolongo c A. Chouker a M. Thiel a G. Schelling a

Departments of a Anesthesiology and b Clinical Chemistry, Ludwig Maximilians University, Munich, Germany; c Department of Human Physiology and Pharmacology, University of Rome La Sapienza, Rome, Italy

Key Words
Complex regional pain syndrome · Stress · Pain · Endocannabinoid · Anandamide

Abstract
The complex regional pain syndrome (CRPS) is a disabling neuropathic pain condition that may develop following injuries of the extremities. The pathogenesis of this syndrome is not clear; however, it includes complex interactions between the nervous and the immune system resulting in chronic inflammation, pain and trophic changes. This interaction may be mediated by chronic stress which is thought to activate the endogenous cannabinoid (endocannabinoid) system (ECS). We conducted an open, prospective, comparative clinical study to determine plasma level of the endocannabinoid anandamide by high-performance liquid chromatography and a tandem mass spectrometry system in 10 patients with CRPS type I versus 10 age- and sex-matched healthy controls. As compared to healthy controls, CRPS patients showed significantly higher plasma concentrations of anandamide. These results indicate that the peripheral ECS is activated in CRPS. Further studies are warranted to evaluate the role of the ECS in the limitation of inflammation and pain.

I.K. and D.H. contributed equally to this work.

Introduction
The complex regional pain syndrome (CRPS) is characterized by neuropathic pain, sensory disturbances, trophic, autonomic and motor changes of the affected extremity [1, 2]. The pathogenesis of this syndrome may include abnormal neuronal processing and central sensitization [3–5] as well as complex communications between the nervous and the immune system resulting in chronic inflammation, pain and trophic changes [6] which are mediated in part by catecholamines and stress [7, 8]. The endocannabinoid system (ECS) has recently been shown to represent a critical mediator between stress, neuropathic pain and immunologic changes including neuroinflammation [9] and may therefore play a role in the development and symptom persistence in CRPS. The ECS includes the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG) [10] which are functionally related to Δ9-tetrahydrocannabinol. Two different types of G protein-coupled receptors, namely CB1 receptors which are found mainly in the central nervous system [11] and CB2 receptors with a peripheral distribution, especially on immunocompetent cells [12, 13], and the transient receptor potential vanilloid 1 (TRPV1) channels [14] mediate the effects of the endocannabinoids. Based on experiments in rodents, both CB1 and CB2 receptors participate in central and peripheral cannabinoid-induced analgesia [15, 16] and anti-inflammation.
tion [17, 18], and appear to be activated under conditions of stress [9, 19]. The TRPV1 channel is involved in the control of neurotransmitter release [14].

Very little is known about the role of the ECS in humans with neuropathic pain in general and with CRPS in particular. We therefore measured the endocannabinoid anandamide in plasma of patients with CRPS. Our primary hypothesis to be tested was that the peripheral ECS is activated, and thus anandamide levels are elevated in patients with CRPS compared to healthy participants.

Materials and Methods

Patients
Ten female CRPS type I patients (46.0 ± 10.7 years, range 20–55) admitted to the Interdisciplinary Pain Clinic of the Department of Anesthesiology of the University of Munich, Germany, were enrolled for blood withdrawal (table 1) if they provided informed consent (local ethics committee protocol No. 324/02) and met the criteria for CRPS type I as proposed by the International Association for the Study of Pain [20] and Bruehl et al. [21]. Ten age- and sex-matched healthy individuals (7 female; 3 male; 41.9 ± 7.3 years, range 34–50) who were completely free of medication served as controls. Exclusion criteria were pregnancy, infection or other inflammation disorders, cancer, muscle or joint diseases, motor trauma and treatment with glucocorticoids or other immunosuppressive drugs. All subjects had abstained from their medication for at least 24 h before blood sampling. In CRPS patients, we determined the duration and localization of the disorder, and the pain intensities on a visual analogue scale (pain scores, 10-cm scale). The Mainz Pain Staging System was used to classify pain chronicity [22]. The incidence and intensity of chronic stress symptoms were evaluated by the Posttraumatic Stress Symptom-10 questionnaire [23].

Biochemical Measurements and Anandamide Determination
All biochemical measurements were conducted in a blinded fashion with regard to group assignment of patients and controls. Venous blood sampling (500 μl) was performed from the unaffected limb. Because of effects of circadian rhythm on endocrine measurements, the time point of blood sampling during the day was standardized (between 10 and 11 a.m.) as was the time interval from blood sampling until processing which ranged from 7 to 10 min and did not differ between the groups (p > 0.50). This time interval is particularly important with regard to endocannabinoid measurements [24].

For determination of anandamide concentrations, we applied automated on-line solid phase extraction using column switching with subsequent direct transfer to high-performance liquid chromatography and a tandem mass spectrometry system (Waters Quattro Ultima Pt; Waters Corporation, Milford, Mass., USA) with stable isotope-labeled anandamide (4-fold deuterated) as the internal standard. Electrospray ionization in the positive mode was used; the following mass transitions were monitored: native anandamide, 348 > 62 and 4d3-anandamide (internal standard), 352 > 66. Our method has a linear response from 100 to 1 μg/l anandamide and a total coefficient of variation of 10.6% at a mean concentration of 8.5 μg/l [24].

Furthermore, a standard set of laboratory values (hemoglobin, leukocyte counts, C-reactive protein) was measured in both patients and healthy controls.

Statistics
Normal distribution of sample data was confirmed by the Kolmogorov-Smirnov test. Geometric means were compared by Student’s t test and considered to be significantly different at p < 0.05. Results are expressed as means ± standard deviation.

Results

Patient Characterization
There was no significant difference with regard to age (46.0 ± 10.7 years, range 20–55 vs. 41.9 ± 7.3 years, range 34–50; p = 0.33) and sex distribution (p = 0.21) between CRPS patients and controls.

CRPS patients had a mean disease duration of 22 months. The mean pain score in CRPS patients was 3.9 ± 0.5 on the 10-cm visual analogue scale. According to the criteria of the Mainz Pain Staging System classification, 3 patients belonged to stage I, 4 patients had pain chronicity of stage II and 3 patients fulfilled criteria for advanced pain chronification (stage III). The Posttraumatic Stress Symptom-10 score in the CRPS study population was higher (35.2 ± 5.3) than in healthy controls (20.8 ± 4.8; p < 0.01).

Standard Laboratory Values
The standard set of laboratory values in patients with CRPS was in the normal range and not statistically different from healthy controls (data not shown).

Anandamide Concentrations
CRPS patients had significantly higher plasma concentrations (3.97 ± 1.49 ng/ml) of anandamide than healthy controls (1.44 ± 0.36 ng/ml; p < 0.001; 95% confidence interval –3.55 to –1.51; fig. 1). The power of the performed test with α = 0.05 is 0.999.

Discussion
The major finding of this study is an increased plasma concentration of the endocannabinoid anandamide in patients with a long-standing and chronic neuropathic pain syndrome, namely CRPS. Chronic stress as a result of ongoing neuropathic pain or stressful life events is a
common finding in CRPS patients [7, 25], and our patients showed high stress symptoms scores and evidence of long-lasting chronic neuropathic pain.

Anandamide found in peripheral blood is synthesized by nucleated blood cells [24]; the primary stimulus leading to increased endocannabinoid synthesis in blood cells is, however, unknown. The peripheral ECS in humans has been shown to be activated by stressful physical exercise [26] and deactivated by the induction of general anesthesia which leads to a pronounced stress reduction [27]. Furthermore, elevated anandamide levels have been described in patients with a stress-related disorder, namely fibromyalgia [28]. Likewise, in animals, massive emotional stress has been identified as a key stimulus regulating endocannabinoid synthesis [29].

The pathophysiological relevance of the enhanced anandamide levels in CRPS patients is still unclear. Using various experimental paradigms which involved stress, pain and memory [30–32], inhibitory endocannabinoid activity has been demonstrated in the amygdala, a key brain area for the encoding and consolidation of traumatic information [33]. One could therefore speculate that the increased activity of the peripheral ECS observed in our study is related to continuous stress exposure and suggests a possible protective role for the ECS in the modulation of neuropathic pain and pain memory [34]. These protective effects of endocannabinoids may also include stress-induced analgesia, both on a central [35] and a peripheral level [15]. Using murine models, stress induced a rapid anandamide release in several central nervous system regions resulting in stress-induced analgesia via CB$_1$ receptors [35, 36]. In addition, a very recent study has shown that endocannabinoids mediate analgesia via stimulation of peripheral CB$_1$ receptors in mice [15].

A further protective effect of the ECS may result from well-known anti-inflammatory effects via CB$_2$ receptors [37] on a variety of innate and adaptive immune functions [38]. Animal and in vitro experiments revealed that cellular effects of cannabinoids include modulation of chemotaxis of macrophage-like cells [39], migration of natural killer cells [40], modification of oxidative burst of neutrophils [41], and attenuation of B and T cell subset formations [42], thereby contributing to anti-inflammatory host defense mechanisms of the organism. In fact, inflammation control by enhanced anandamide levels has been described for experimentally induced colon inflammation [43], cholera toxin-induced diarrhea [44], and in patients with inflammatory gastrointestinal diseases [45]. In patients with another stress-related disorder, namely fibromyalgia, a strong, positive relationship between anandamide levels and the adhesive and phagocytic functions of neutrophils was found. Moreover, multiple backward regression analysis revealed plasma concentration of anandamide to be the main factor in determining adhesion and phagocytosis capacity of neutrophils [28]. Thus, the upregulation of peripheral anandamide levels seen in our patients might be regarded as an endogenous mechanism to protect from pain and to limit inflammation.
Our study has several limitations, however. We studied only a small number of subjects, and this makes it difficult to generalize our findings to other patient groups with CRPS. Additionally, interindividual differences preponderate in such small patient groups. On the other hand, the patient and the control groups in our study were well matched, and the differences between both groups with regard to the hypothesis under study were large and statistically significant. A further limitation is that we determined only anandamide and did not measure other important endocannabinoids such as 2-AG. The determination of 2-AG carries several methodological problems, however, which result from spontaneous isomerization to biologically inactive 1-AG [46, 47] which may occur in vivo and in vitro with the consequence of imprecise measurements [48].

In conclusion, our study has shown for the first time that the peripheral ECS is activated in highly stressed individuals with CRPS. With respect to the pain-limiting and anti-inflammatory actions of the endocannabinoid anandamide, it is suggested that the elevated anandamide level is probably autoprotective and CRPS patients might therefore benefit from pharmacologic manipulation of cannabinoid receptor-dependent signaling.

References
